ArticleScience translational medicine2017

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.

Donald M O'Rourke et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.